The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery
Open accessAbstract
Knowledge and investigation of therapeutic targets (responsible for drug efficacy) and the targeted drugs facilitate target and drug discovery and validation. Therapeutic Target Database (TTD, http://bidd.nus.edu.sg/group/ttd/ttd.asp) has been developed to provide comprehensive information about efficacy targets and the corresponding approved, clinical trial and investigative drugs. Since its last update, major improvements and updates have been made to TTD. In addition to the significant increase of data content (from 1894 targets and 5028 drugs to 2025 targets and 17,816 drugs), we added target validation information (drug potency against target, effect against disease models and effect of target knockout, knockdown or genetic variations) for 932 targets, and 841 quantitative structure activity relationship models for active compounds of 228 chemical types against 121 targets. Moreover, we added the data from our previous drug studies including 3681 multi-target agents against 108 target pairs, 116 drug combinations with their synergistic, additive, antagonistic, potentiative or reductive mechanisms, 1427 natural product-derived approved, clinical trial and pre-clinical drugs and cross-links to the clinical trial information page in the ClinicalTrials.gov database for 770 clinical trial drugs. These updates are useful for facilitating target discovery and validation, drug lead discovery and optimization, and the development of multi-target drugs and drug combinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Database resources of the National Center for Biotechnology Information: update
Wheeler, D. L. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh073 · Cited by 10,641
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities
Liu, T., Lin, Y., Wen, X., Jorissen, R. N., & Gilson, M. K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl999 · Cited by 2,124
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
Li, J. W.-H., & Vederas, J. C. (2009) · Science · doi:10.1126/science.1168243 · Cited by 2,052
DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1126 · Cited by 1,831
Virtual Computational Chemistry Laboratory – Design and Description
Tetko, I. V., Gasteiger, J., Todeschini, R., Mauri, A., Livingstone, D., Ertl, P., Palyulin, V. A., Radchenko, E. V., Zefirov, N. S., Makarenko, A. S., et al. (2005) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-005-8694-y · Cited by 1,500
Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
Overall, C. M., & Kleifeld, O. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1821 · Cited by 1,214
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 991
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
Self-citationTrends in the exploitation of novel drug targets
Rask-Andersen, M., Almén, M. S., & Schiöth, H. B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3478 · Cited by 853
Multicomponent therapeutics for networked systems
Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769
TTD: Therapeutic Target Database
Chen, X. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.412 · Cited by 716
Identifying regulatory networks by combinatorial analysis of promoter elements
Pilpel, Y., Sudarsanam, P., & Church, G. M. (2001) · Nature Genetics · doi:10.1038/ng724 · Cited by 652
Comparison of Automatic Three-Dimensional Model Builders Using 639 X-ray Structures
Sadowski, J., Gasteiger, J., & Klebe, G. (1994) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00020a039 · Cited by 646
Database resources of the National Center for Biotechnology Information
Sayers, E. W., Barrett, T., Benson, D. A., Bolton, E., Bryant, S. H., Canese, K., Chetvernin, V., Church, D. M., DiCuccio, M., Federhen, S., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1172 · Cited by 638
Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy
Larder, B. A., Kemp, S. D., & Harrigan, P. R. (1995) · Science · doi:10.1126/science.7542804 · Cited by 623
Plant-derived compounds in clinical trials
Saklani, A., & Kutty, S. K. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.010 · Cited by 477
Smalley, K. S. M., Haass, N. K., Brafford, P. A., Lioni, M., Flaherty, K. T., & Herlyn, M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0084 · Cited by 463
Computational Methods in Developing Quantitative Structure-Activity Relationships (QSAR): A Review
Dudek, A., Arodz, T., & Galvez, J. (2006) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620706776055539 · Cited by 429
Knockouts model the 100 best-selling drugs—will they model the next 100?
Zambrowicz, B. P., & Sands, A. T. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd987 · Cited by 393
Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders
Youdim, M. B. H., & Buccafusco, J. J. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.11.007 · Cited by 380
Lindsay, M. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1202 · Cited by 332
Privileged Structures: A Useful Concept for the Rational Design of New Lead Drug Candidates
Duarte, C., Barreiro, E., & Fraga, C. (2007) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955707782331722 · Cited by 308
Assessing drug-likeness – what are we missing?
Vistoli, G., Pedretti, A., & Testa, B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.007 · Cited by 278
Update of TTD: Therapeutic Target Database
Zhu, F., Han, B., Kumar, P., Liu, X., Ma, X., Wei, X., Huang, L., Guo, Y., Han, L., Zheng, C., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp1014 · Cited by 274
Self-citationClustered patterns of species origins of nature-derived drugs and clues for future bioprospecting
Zhu, F., Qin, C., Tao, L., Liu, X., Shi, Z., Ma, X., Jia, J., Tan, Y., Cui, C., Lin, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107336108 · Cited by 255
Self-citationTherapies for Alzheimer's disease
Melnikova, I. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2314 · Cited by 219
Target selection in drug discovery
Knowles, J., & Gromo, G. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd986 · Cited by 216
Therapeutic Targets: Progress of Their Exploration and Investigation of Their Characteristics
Zheng, C. J., Han, L. Y., Yap, C. W., Ji, Z. L., Cao, Z. W., & Chen, Y. Z. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.2.4 · Cited by 185
Self-citationWarr, W. A. (2009) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-009-9260-9 · Cited by 176
The basics of preclinical drug development for neurodegenerative disease indications
Steinmetz, K. L., & Spack, E. G. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-s1-s2 · Cited by 165
Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective
Zhao, H. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.12.003 · Cited by 159
In-Silico Approaches to Multi-target Drug Discovery
Xiao, H., Shi, Z., Tan, C., Jiang, Y., Go, M., Low, B. C., & Chen, Y. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0065-2 · Cited by 144
Self-citationDrug Discovery in the Next Millennium
Ohlstein, E. H., Ruffolo, R. R., Jr., & Elliott, J. D. (2000) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.177 · Cited by 115
Progress and problems in the exploration of therapeutic targets
Zheng, C., Han, L., Yap, C. W., Xie, B., & Chen, Y. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.03.012 · Cited by 62
Self-citationH., X., Wang, R., Tan, C., Jiang, Y., Lu, T., Rao, H., Li, X., Go, M., Low, B. C., & Chen, Y. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100179t · Cited by 60
Self-citationZhu, F., Han, L., Zheng, C., Xie, B., Tammi, M. T., Yang, S., Wei, Y., & Chen, Y. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.149955 · Cited by 50
Self-citationCurrent trends in the clinical development of peptide therapeutics.
Saladin, P. M., Zhang, B. D., & Reichert, J. M. (2009) · PubMed · Cited by 48
Challenges in Analgesic Drug Development
Hewitt, D., Hargreaves, R. J., Curtis, S., & Michelson, D. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.161 · Cited by 48
Melnikova, I. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2443 · Cited by 46
Melnikova, I. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2511 · Cited by 40
Comparison Data Sets for Benchmarking QSAR Methodologies in Lead Optimization
Mittal, R. R., McKinnon, R. A., & Sorich, M. J. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900117m · Cited by 28
Killing two kinase families with one stone
Bilanges, B., Torbett, N. E., & Vanhaesebroeck, B. (2008) · Nature Chemical Biology · doi:10.1038/nchembio1108-648 · Cited by 28
Vidalin, O., Muslmani, M., Estienne, C., Echchakir, H., & Abina, A. M. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.017 · Cited by 21
Cited by
Genetics of rheumatoid arthritis contributes to biology and drug discovery
the RACI consortium, Okada, Y., the GARNET consortium, Wu, D., Trynka, G., Raj, T., Terao, C., Ikari, K., Kochi, Y., Ohmura, K., et al. (2014) · Nature · doi:10.1038/nature12873 · Cited by 2,310
STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data
Szklarczyk, D., Santos, A., von Mering, C., Jensen, L. J., Bork, P., & Kuhn, M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1277 · Cited by 1,687
The druggable genome and support for target identification and validation in drug development
Finan, C., Gaulton, A., Kruger, F. A., Lumbers, R. T., Shah, T., Engmann, J., Galver, L., Kelley, R., Karlsson, A., Santos, R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1166 · Cited by 1,026
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
Pawson, A. J., Sharman, J. L., Benson, H. E., Faccenda, E., Alexander, S. P. H., Buneman, O. P., Davenport, A. P., McGrath, J. C., Peters, J. A., Southan, C., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1143 · Cited by 849
Metadata
- Authors
- Zhu, F., Shi, Z., Qin, C., Tao, L., Liu, X., Xu, F., Zhang, L., Song, Y., Liu, X., Zhang, J., Han, B., Zhang, P., & Chen, Y.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-09-24
- Volume
- 40
- Issue
- D1
- Pages
- D1128-D1136
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W1983248350
- Cited by
- 480
- References
- 50
- FWCI
- 33.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.